

# Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/C0049438E0D7EN.html>

Date: December 2019

Pages: 173

Price: US\$ 3,500.00 (Single User License)

ID: C0049438E0D7EN

## Abstracts

Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

### SUMMARY

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 32 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 4, 7, 3, 8 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease, Metabolic Disorders and Toxicology which include indications Breast Cancer, Non-Small Cell Lung Cancer, Mantle Cell Lymphoma, Metastatic Breast Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Metastatic Colorectal Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Hepatocellular Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Bladder Cancer, Colon Cancer, Dedifferentiated Liposarcoma, Epithelial Ovarian Cancer, Esophageal Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemia,

Liposarcoma, Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Thymic Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Induced Myelosuppression, Chordoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Head And Neck Cancer, High-Grade Glioma, Hormone Sensitive Breast Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Kidney Cancer (Renal Cell Cancer), Lung Cancer, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Medulloblastoma, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Nonmelanomatous Skin Cancer, Primary CNS Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer), Type 2 Diabetes and Well Differentiated Liposarcoma.

The latest report Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019, outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Overview

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Companies Involved in Therapeutics Development

Beta Pharma Inc

Betta Pharmaceuticals Co Ltd

CStone Pharmaceuticals Co Ltd

Eli Lilly and Co

ESSA Pharma Inc

Fochon Pharmaceutical Ltd

G1 Therapeutics Inc

Guangzhou BeBetter Medicine Technology Co Ltd

HEC Pharm Co Ltd

Jiangsu Hansoh Pharmaceutical Group Co Ltd

Jiangsu Hengrui Medicine Co Ltd

MEI Pharma Inc

Novartis AG

Onconova Therapeutics Inc

Pfizer Inc

Rizen (Suzhou) Biosciences Co Ltd

Shanghai Haihe Biopharma Co Ltd

Shanghai Haishi Biopharmaceutical Co Ltd

Shanghai Pharmaceutical Group Co Ltd

SignalRx Pharmaceuticals Inc

Sihuan Pharmaceutical Holdings Group Ltd

Sino Biopharmaceutical Ltd

Tetranov International Inc

Tiziana Life Sciences Plc

ViroStatics SRL

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC

2.7.11.22) - Drug Profiles

abemaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BEBT-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-1178 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BPI-16350 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-3002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit CDK4 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FCN-437c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GZ-381 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEC-80797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HS-10342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JS-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ierociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

milciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-108110 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ON-123300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06873600 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ribociclib succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SHR-6390 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK1, CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Colorectal Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4 and CDK6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CDK4/6 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target AR, CDK4 and CDK6 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4 and CDK6 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRX-3177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TQ-05510 - Drug Profile



Product Description

Mechanism Of Action

R&D Progress

trilaciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

voruciclib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VS-2370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XZP-3287 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Dormant Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Product Development Milestones

Featured News & Press Releases

Dec 11, 2019: Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3

Dec 11, 2019: G1 Therapeutics presents updated data from phase 1b/2a trial of oral CDK4/6 inhibitor Lerociclib at 2019 San Antonio Breast Cancer Symposium (SABCS)

Dec 11, 2019: Combining endocrine therapy with a CDK4/6 Inhibitor results in similar response rates to chemotherapy for high-risk Luminal B Breast Cancer

Dec 08, 2019: New test predicts chance of living more than a year on targeted breast cancer treatment

Nov 28, 2019: NICE recommends Pfizer's Ibrance for NHS use through the CDF

Nov 11, 2019: Novartis' Kisqali (ribociclib) in combination with fulvestrant receives recommendation from Scottish Medicines Consortium (SMC) for the treatment of patients with the most common form of advanced breast cancer

Oct 03, 2019: MEI pharma announces updated clinical data from voruciclib

Sep 30, 2019: ESMO 2019: Kisqali shows superior overall survival in breast cancer

Sep 29, 2019: Verzenio (abemaciclib) significantly extends life by a Median of 9.4 months for women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 study

Sep 28, 2019: G1 Therapeutics presents updated data at ESMO 2019 from randomized phase 2 trial of Trilaciclib in combination with chemotherapy in metastatic triple-negative breast cancer demonstrating significant improvement in overall survival

Sep 26, 2019: Addition of KISQALI to drug plan in Quebec expands access to treatment for metastatic breast cancer

Sep 24, 2019: Pfizer presents new evidence of IBRANCE (palbociclib) effectiveness in HR+, HER2- metastatic breast cancer patients in four real-world studies at ESMO Congress 2019

Sep 23, 2019: Lilly Oncology to present robust data on VERZENIO (abemaciclib) at ESMO 2019

Sep 10, 2019: G1 Therapeutics to present new clinical data on Lerociclib (G1T38) at European Society for Medical Oncology (ESMO) 2019 Congress

Sep 10, 2019: G1 Therapeutics to present new clinical data on Trilaciclib at European Society for Medical Oncology (ESMO) 2019 Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1)

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Products under Development by Companies, H2 2019 (Contd..8), H2 2019

Products under Development by Companies, H2 2019 (Contd..9), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Beta Pharma Inc, H2 2019

Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019

Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by ESSA Pharma Inc, H2 2019

Pipeline by Fochon Pharmaceutical Ltd, H2 2019

Pipeline by G1 Therapeutics Inc, H2 2019

Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H2 2019

Pipeline by HEC Pharm Co Ltd, H2 2019

Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H2 2019

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019

Pipeline by MEI Pharma Inc, H2 2019  
Pipeline by Novartis AG, H2 2019  
Pipeline by Onconova Therapeutics Inc, H2 2019  
Pipeline by Pfizer Inc, H2 2019  
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2019  
Pipeline by Shanghai Haihe Biopharma Co Ltd, H2 2019  
Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H2 2019  
Pipeline by Shanghai Pharmaceutical Group Co Ltd, H2 2019  
Pipeline by SignalRx Pharmaceuticals Inc, H2 2019  
Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H2 2019  
Pipeline by Sino Biopharmaceutical Ltd, H2 2019  
Pipeline by Tetranov International Inc, H2 2019  
Pipeline by Tiziana Life Sciences Plc, H2 2019  
Pipeline by ViroStatics SRL, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Dormant Products, H2 2019 (Contd..2), H2 2019  
Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Top 10 Indications, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Routes of Administration, H2 2019  
Number of Products by Stage and Routes of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019

### COMPANIES MENTIONED

Beta Pharma Inc  
Betta Pharmaceuticals Co Ltd  
CStone Pharmaceuticals Co Ltd  
Eli Lilly and Co  
ESSA Pharma Inc  
Fochon Pharmaceutical Ltd  
G1 Therapeutics Inc  
Guangzhou BeBetter Medicine Technology Co Ltd  
HEC Pharm Co Ltd  
Jiangsu Hansoh Pharmaceutical Group Co Ltd  
Jiangsu Hengrui Medicine Co Ltd  
MEI Pharma Inc  
Novartis AG  
Onconova Therapeutics Inc  
Pfizer Inc  
Rizen (Suzhou) Biosciences Co Ltd  
Shanghai Haihe Biopharma Co Ltd  
Shanghai Haishi Biopharmaceutical Co Ltd  
Shanghai Pharmaceutical Group Co Ltd  
SignalRx Pharmaceuticals Inc  
Sihuan Pharmaceutical Holdings Group Ltd  
Sino Biopharmaceutical Ltd  
Tetranov International Inc  
Tiziana Life Sciences Plc  
ViroStatics SRL

## I would like to order

Product name: Cyclin Dependent Kinase 4 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C0049438E0D7EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C0049438E0D7EN.html>